Xin Lang Cai Jing·2026-03-12 06:41Core Viewpoint - Goldman Sachs reports that Kanglong Chemical has reached a cooperation agreement with Eli Lilly to support the local supply of Orforglipron in China, with Eli Lilly expected to invest $200 million to enhance Kanglong's technical capabilities [1] Group 1: Partnership Details - The partnership is anticipated to expand as the project progresses, with further assessments of its impact on Kanglong's fundamentals depending on additional disclosures [1] - The upcoming earnings call is expected to provide more details on the cooperation model, potential order scale, and the commercialization trajectory of Orforglipron in China [1] Group 2: Market Reaction and Ratings - The partnership is expected to generate a positive market response for Kanglong, highlighting Eli Lilly's recognition of Kanglong as a qualified partner in the local GLP-1 supply chain [1] - Goldman Sachs has assigned a "Buy" rating for Kanglong's Hong Kong shares with a target price of HKD 30.7, and a "Neutral" rating for its A-shares with a target price of CNY 38 [1]